These effects are attributed to the HDAC6 inhibitor-induced inhibition of mitogen-activated protein kinase 7 (MKK7), which has been identified as crucial in JNK activation and carcinogenesis in glioma cells [22]. This evidence concerns the gene MAP3K7 and central nervous system cancer.